ClinicalTrials.gg
RecruitingNCT04634591BBSSUpdated Apr 14, 2026

The Bialystok Bariatric Surgery Study

An observational study in Obesity, Diabetes Mellitus and Metabolic Syndrome, sponsored by Medical University of Bialystok. Recruiting at 1 site in Poland. Open to participants aged 18 Years and older, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-04-14.

Sponsored by Medical University of Bialystok · Observational

How we know

From the registry’s dates

  • Started Sep 2015; still recruiting 11 years 2 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Case-control
Time perspective
Prospective
Enrollment
1,000
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-21

Among 16 studies in Obesity by Medical University of Bialystok — 4 open to participants now, 4 under way, none of them phase 3. Obesity · Medical University of Bialystok.

Started
2015
the only one that year
Observational
8 of 16
3 open now
Registered
3rd of 16
by date

Among the 16 studies in Obesity by Medical University of Bialystok, this one is the only one that started in 2015, is one of 8 observational ones, and was the 3rd registered.

Obesity

11,564 studies on the registry are indexed under Obesity; 2,063 are open to participants now.

Browse Obesity studies →

Open to participants now

4 of the 16 studies in Obesity by Medical University of Bialystok are open now, in 1 country. Recruiting first, the newest first:

By country, each count listing its studies:

All 4 open studies →

Where they have run

Who these studies take

Of the 1,352 Obesity studies recruiting now, 382 (28%) set no upper age limit and 867 (64%) stop at 75 or younger; 169 take children under 18; 491 take healthy volunteers.

This study: 18 Years and older · all sexes · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 16 studies in Obesity by Medical University of Bialystok, or all of them as a file.
02

Study summary

The Bialystok Bariatric Surgery Study (BBSS) is a prospective observational cohort study of patients undergoing bariatric surgery at the First Clinical Department of General and Endocrine Surgery at the Medical University of Bialystok. The BBSS consists of a battery of baseline tests established one month prior to the surgery and repeated at one, three, six, twelve and twenty four-month follow-up clinical visits.

03

Conditions studied

  • Obesity
  • Diabetes Mellitus
  • Metabolic Syndrome
  • Dyslipidemias
  • PreDiabetes

Keywords

  • bariatric surgery
  • diabetes treatment
  • prediabetes treatment
  • metabolic surgery
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
Yes
Sampling method
Probability sample

Study population

In Bialystok Bariatric Surgery Study (BBSS), we observe a cohort study of patients who undergo bariatric surgery in the First Clinical Department of General and Endocrine Surgery of the Medical University of Bialystok. This center performs several types of bariatric surgery including Roux-en-Y gastric bypass (RYGB), adjustable gastric banding (AGB), and sleeve gastrectomy (SG) in patients referred to the clinic by general practitioners and endocrinologists and who were qualified for the surgery according to the clinical physicians. Only patients who agreed to participate in the research project, specified in detail during written and oral patients consent, are included. Moreover, the study population consists of the group of obese patients who do not undergo the surgery and are followed-up without the surgical intervention and the non-obese control group of patients without obesity.

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • ≥ 40 kg/m2, or BMI ≥ 35 and at least one or more obesity-related co-morbidities such as type 2 diabetes (T2D), hypertension, sleep apnea and other respiratory disorders, non-alcoholic fatty liver disease, osteoarthritis, lipid abnormalities, gastrointestinal disorders, or heart disease.
  • Inability to achieve a healthy weight loss sustained for a period of time with prior weight loss efforts
  • Patient consent for participation in research project
  • Willingness in participation in follow-up visits

Exclusion criteria

Exclusion Criteria:

  • substance abuse,
  • uncontrolled psychiatric illness
  • expected lack of compliance
  • advanced-stage cancer

Non-obese control group:

  • \<30
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

05

Study design

Observational model
Case-control
Time perspective
Prospective
Enrollment
1,000 participants (estimated)
Patient registry
No

Groups and cohorts

  • Obesity - undergoing bariatric surgery

    Patients with morbid obesity, treated with the bariatric surgery

    Procedure: Bariatric surgery

  • Obesity - without bariatric surgery treatment

    Patients with morbid obesity, not treated with the bariatric surgery

  • Non-obese

    Non-obese patients - control group (without obesity and without the bariatric surgery treatment)

Interventions

  • ProcedureBariatric surgery

    Bariatric surgery (Roux-en-Y gastric bypass, gastric banding, or sleeve gastrectomy) for the treatment of morbid obesity

    Also known as: Metabolic surgery

06

What researchers measure

Primary outcomes

  1. Weight loss

    Changes in total body weight under the surgery

    Time frame: 1, 3, 6, 12 and 24 months after the surgery

  2. Lean body mass

    Changes in total lean body mass under the surgery, measured using the whole-body dual-energy X-ray absorptiometry (DXA)

    Time frame: 1, 3, 6, 12 and 24 months after the surgery

  3. Fat mass

    Changes in total fat mass under the surgery, measured using the whole-body dual-energy X-ray absorptiometry (DXA)

    Time frame: 1, 3, 6, 12 and 24 months after the surgery

  4. Visceral adipose tissue mass

    Changes in visceral adipose tissue mass under the surgery, measured using the whole-body dual-energy X-ray absorptiometry (DXA)

    Time frame: 1, 3, 6, 12 and 24 months after the surgery

  5. Fasting glucose

    Changes in fasting glucose concentration under the surgery, measured in plasma using the colorimetric method

    Time frame: 1, 3, 6, 12 and 24 months after the surgery

  6. Triglycerides (TG)

    Changes in serum triglycerides concentration under the surgery, measured using the colorimetric method

    Time frame: 1, 3, 6, 12 and 24 months after the surgery

  7. High-density lipoprotein cholesterol (HDL)

    Changes in serum High-density lipoprotein cholesterol (HDL) concentration under the surgery, measured using the colorimetric method

    Time frame: 1, 3, 6, 12 and 24 months after the surgery

  8. Low-density lipoprotein cholesterol (LDL)

    Changes in serum Low-density lipoprotein cholesterol (LDL) concentration under the surgery, measured using the colorimetric method

    Time frame: 1, 3, 6, 12 and 24 months after the surgery

  9. Total cholesterol

    Changes in serum total cholesterol concentration under the surgery, measured using the colorimetric method

    Time frame: 1, 3, 6, 12 and 24 months after the surgery

  10. Fasting insulin

    Changes in fasting insulin concentration under the surgery, measured by the immunoradiometric assay (IRMA)

    Time frame: 1, 3, 6, 12 and 24 months after the surgery

  11. 2-hour glucose

    Changes in glucose concentration at 2-hour of the oral glucose tolerance test under the surgery, measured in plasma using the colorimetric method

    Time frame: 1, 3, 6, 12 and 24 months after the surgery

  12. Haemoglobin A1c (HbA1c)

    Changes in Haemoglobin A1c under the surgery, measured by the high-performance liquid chromatography (HPLC) method

    Time frame: 1, 3, 6, 12 and 24 months after the surgery

  13. Homeostatic model assessment for insulin resistance (HOMA-IR)

    Changes in Homeostatic model assessment for insulin resistance under the surgery

    Time frame: 1, 3, 6, 12 and 24 months after the surgery

  14. Homeostatic model assessment of beta cell function (HOMA-beta)

    Changes in Homeostatic model assessment of beta cell function under the surgery

    Time frame: 1, 3, 6, 12 and 24 months after the surgery

  15. Changes in glucose and insulin concentrations during the oral glucose tolerance test (OGTT)

    Changes in concentrations of glucose and insulin during the oral glucose tolerance test, under the surgery

    Time frame: 1, 3, 6, 12 and 24 months after the surgery

  16. Changes in glucose and insulin concentrations during the mixed meal tolerance test (MMTT)

    Changes in concentrations of glucose and insulin during the mixed meal tolerance test, under the surgery

    Time frame: 1, 3, 6, 12 and 24 months after the surgery

  17. Changes in GI hormones concentrations during the oral glucose tolerance test (OGTT)

    Changes in concentrations of gastrointestinal hormones during the oral glucose tolerance test, under the surgery

    Time frame: 1, 3, 6, 12 and 24 months after the surgery

  18. Changes in GI hormones concentrations during the mixed meal tolerance test (MMTT)

    Changes in concentrations of gastrointestinal hormones during the mixed meal tolerance test, under the surgery

    Time frame: 1, 3, 6, 12 and 24 months after the surgery

Secondary outcomes

  1. Plasma metabolome

    Changes in plasma metabolites concentrations measured using untargeted metabolomics, in response to the surgery

    Time frame: 1, 3, 6, 12 and 24 months after the surgery

  2. Plasma proteome

    Changes in plasma proteins concentrations measured using targeted and untargeted proteomics, in response to the surgery

    Time frame: 1, 3, 6, 12 and 24 months after the surgery

  3. Urine metabolome

    Changes in urine metabolites concentrations measured using untargeted metabolomics, in response to the surgery

    Time frame: 1, 3, 6, 12 and 24 months after the surgery

  4. Skeletal muscle transcriptome

    Changes in skeletal muscle gene and small RNA expressions measured using untargeted transcriptomics, in response to the surgery

    Time frame: 1, 3, 6, 12 and 24 months after the surgery

  5. Liver transcriptome

    Changes in liver gene and small RNA expressions measured using untargeted transcriptomics, in response to the surgery

    Time frame: 1, 3, 6, 12 and 24 months after the surgery

  6. Adipose tissue transcriptome

    Changes in adipose tissue gene and small RNA expressions measured using untargeted transcriptomics, in response to the surgery

    Time frame: 1, 3, 6, 12 and 24 months after the surgery

  7. Circulating microRNA

    Changes in circulating microRNAs expression, in response to the surgery

    Time frame: 1, 3, 6, 12 and 24 months after the surgery

  8. Liver methylome

    Changes in liver DNA methylations measured using Reduced representation bisulfite sequencing (RRBS) method, in response to the surgery

    Time frame: 1, 3, 6, 12 and 24 months after the surgery

  9. Skeletal muscle methylome

    Changes in skeletal muscle DNA methylations measured using Reduced representation bisulfite sequencing (RRBS) method, in response to the surgery

    Time frame: 1, 3, 6, 12 and 24 months after the surgery

  10. Adipose tissue methylome

    Changes in adipose tissue DNA methylations measured using Reduced representation bisulfite sequencing (RRBS) method, in response to the surgery

    Time frame: 1, 3, 6, 12 and 24 months after the surgery

07

Study locations

1 of 1 sites recruiting
  • Clinical Research Centre, Medical University of Bialystok
    Bialystok, Podlaskie Voivodeship 15-276, Poland
    Recruiting
    • Lukasz Szczerbinski, MD, PhD · Contactlukasz.szczerbinski@umb.edu.pl · +48 85 831 81 50
    • Adam Kretowski, Prof., MD, PhD · Principal investigator
    • Lukasz Szczerbinski, MD, PhD · Principal investigator
08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Sep 2015 (actual). Primary completion is estimated for Dec 2026, 135 months after the start.

Of 796 non-industry observational studies under Obesity, half reached primary completion within 40 months of starting (the median), counting those still running; a quarter within 17 and three quarters within 106. This study's planned 135 months is above that.

Counting every sponsor, half of 842 studies reached it within 39 months; a quarter within 17 and three quarters within 96.

How these figures are worked out, and which studies are left out of them.

Registered
Nov 12, 2020
First posted
Nov 18, 2020
StartActual
Sep 10, 2015
Primary completionEst.
Dec 31, 2026
CompletionEst.
Dec 31, 2026
Last update
Apr 14, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Apr 14, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT04634591
Lead sponsor
Medical University of Bialystok
Responsible party
Sponsor
First posted
Nov 18, 2020
Start date
Sep 10, 2015
Primary completion
Dec 31, 2026 (estimated)
Completion
Dec 31, 2026 (estimated)
Last update
Apr 14, 2026

Oversight

FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

No contact was published for this record. The registry link below has the sponsor’s details.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion